SEKISUI Diagnostics to Provide Metrix® COVID/Flu Test to the Point-of-Care and Home Test Markets
BURLINGTON, Mass., April 2, 2025 /PRNewswire/ -- SEKISUI Diagnostics, a global medical diagnostics manufacturer, announces the launch of the Metrix®...
COVID-19
CORRECTING and REPLACING ExThera Medical Receives MTEC Award for Pivotal Sepsis Trial
Randomized trial at LSU Health Shreveport will evaluate Seraph 100 Blood Filter's effectiveness in treating sepsis caused by wound infections....
Traws Pharma Reports Full Year 2024 Results and Business Highlights
Tivoxavir marboxil’s potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well...
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
MIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading...
Traws Pharma Announces Management Updates
Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman,...
Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results
FORT MILL, S.C., March 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device...
Bio-Path Holdings Reports Full Year 2024 Financial Results
Reports Continued Progress Across Both Obesity and Oncology FranchisesHOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in...
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer...
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease...
Shineco Announces Acquisition of Medical Device Company
The Acquisition is Expected to Create Immediate Synergies with the Company’s Existing Medical Device Business BEIJING, March 25, 2025 (GLOBE...
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with...
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID...
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel,...
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules
WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia
On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL...
IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian...
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate...
Task Trainers Market to Reach $2.9 Billion by 2032–Exclusive Report by Meticulous Research®
REDDING, Calif., March 21, 2025 /PRNewswire/ -- According to a new market research report titled 'Task Trainers Market Size, Share, Forecast,...